However, whether Semaglutide’s effect is mitigating or exacerbating remains unclear, emphasizing the necessity for further research on the outcome of GLP-1R agonists on cancer, specifically thyroid cancer. The gene discussed is GLP1R; the disease is thyroid gland carcinoma.